Assessment of Cognitive Function and Exercise Capacity in Cystic Fibrosis

December 8, 2023 updated by: Deniz Inal-Ince, Hacettepe University

A Comparison of Exercise Capacity, Arterial Stiffness, and Cognitive Function Between Adults With Cystic Fibrosis and Healthy Individuals

No studies in the literature have investigated the simultaneous effects of cognitive function, exercise capacity and arterial stiffness in adult patients with CF. The study aims to compare the cognitive function, exercise capacity, exercise muscle oxygenation, and arterial stiffness of adult patients with CF and healthy subjects.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Cystic fibrosis (CF) affects other body systems as well as the respiratory system. Patients with CF seem to have reduced exercise capacity, which is a major contributor to mortality rates. Changes in lung function, ventilatory dysfunction, and respiratory muscle function potentially contribute to exercise intolerance in CF. Both children and adults with CF exhibit neurocognitive dysfunction. Arterial stiffness is a predictor of cardiovascular events, including myocardial infarction, heart failure, and mortality. Individuals with CF exhibit an increase in arterial stiffness. However, no studies in the literature have investigated cognitive function, exercise capacity, and arterial stiffness coexistence in adult CF patients. The study aims to compare the cognitive function, exercise capacity, exercise muscle oxygenation and arterial stiffness in adult patients with CF and healthy subjects. Additionally, it will determine the relationship between cognitive function and arterial stiffness with exercise capacity and muscle oxygenation during exercise in adult patients with CF.

Study Type

Observational

Enrollment (Estimated)

48

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

24 patients with cystic fibrosis will be included in patients group and 24 healthy individuals will be included in control group.

Description

Inclusion Criteria:

  • Having been diagnosed with cystic fibrosis
  • Being 18 years old and older
  • Clinically stable condition
  • Able to cooperate with the tests performed
  • Volunteered to participate in the study

For the control group:

  • Being 18 years old and older
  • Volunteered to participate in the study

Exclusion Criteria:

  • History of hospitalization or exacerbation in the last month.
  • Chronic respiratory failure and long-term use of oxygen therapy
  • Using noninvasive mechanical ventilator therapy
  • Indication for lung transplantation
  • Who had a lung transplant
  • Forced expiratory volume in the first second (FEV1) value 30% and below
  • CF-related diabetes
  • Chronic liver disease
  • Allergic bronchopulmonary aspergillosis
  • Systemic steroid use
  • History of diagnosed orthopedic or musculoskeletal problems affecting mobility
  • Cardiovascular instability
  • Serious psychiatric illness

For the control group:

  • Known chronic or systemic disease
  • Who did not volunteer to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
cystic fibrosis
No intervention
healthy volunteers
No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exercise capacity
Time Frame: 6 minutes
Exercise capacity is assessed using the 6-minute walk test (6MWT). The 6MWT is performed according to the criteria of the American Thoracic Society.
6 minutes
Arterial Stiffness Assessment
Time Frame: 20 minutes
Arterial stiffness is determined using a oscillometric cuff device (Tel-O-Graph BT, I.E.M., Stolberg, Germany). Pulse wave velocity (PWV) and augmentation index (AIx) are measured by brachial pulse waves.
20 minutes
Cognitive Assessment- MoCA
Time Frame: 10 minutes
Cognitive function is measured using the Montreal Cognitive Assessment (MoCA) test. The MoCA test is a questionnaire developed to evaluate different cognitive functions and mild cognitive impairment. The maximum score that an individual can obtain from the test is 30, and a score of 26 above is considered as mild cognitive impairment.
10 minutes
Cognitive Assessment-Mini Mental Test
Time Frame: 10 minutes
Cognitive function is measured using the Mini Mental Test. A higher score indicates better cognitive function. The maximum score that an individual can obtain from the test is 30, and a score of 23 and above is considered as cognitive impairment.
10 minutes
Muscle Oxygenation Assessment
Time Frame: 10 minutes
Muscle oxygenation (SmO2) is assessed using a measuring and monitoring device (Moxy Fortiori Desing LLC, Minnesota, USA).
10 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body Composition
Time Frame: 5 minutes
Body fat is measured using skinfold thickness assessment.
5 minutes
Pulmonary Function Test (forced vital capacity (FVC))
Time Frame: 10 minutes
Testing procedures is in accordance with the guidelines published by ATS/ERS. A portable spirometer is used for assessment. Pulmonary function testing assesses forced vital capacity (FVC).
10 minutes
Pulmonary Function Test (forced expiratory volume in the first second (FEV1))
Time Frame: 10 minutes
Testing procedures is in accordance with the guidelines published by ATS/ERS. A portable spirometer is used for assessment. Pulmonary function testing assesses forced expiratory volume in the first second (FEV1).
10 minutes
Pulmonary Function Test (FEV1/FVC)
Time Frame: 10 minutes
Testing procedures is in accordance with the guidelines published by ATS/ERS. A portable spirometer is used for assessment. Pulmonary function testing assesses FEV1/FVC.
10 minutes
Pulmonary Function Test (peak flow rate (PEF))
Time Frame: 10 minutes
Testing procedures is in accordance with the guidelines published by ATS/ERS. A portable spirometer is used for assessment. Pulmonary function testing assesses peak flow rate (PEF).
10 minutes
Pulmonary Function Test (forced expiratory flow from 25-75% (FEF25-75%))
Time Frame: 10 minutes
Testing procedures is in accordance with the guidelines published by ATS/ERS. A portable spirometer is used for assessment. Pulmonary function testing assesses forced expiratory flow from 25-75% (FEF25-75%).
10 minutes
Respiratory Muscle Strength
Time Frame: 10 minutes
Maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) are measured using a mouth pressure measuring device with personal antibacterial and antiviral disposable filters.
10 minutes
Peripheral Muscle Strength
Time Frame: 5 minutes
Knee extensor muscle strength is measured utilizing a portable device.
5 minutes
Anxiety and Depression
Time Frame: 5 minutes
The Hospital Anxiety and Depression scale (HADS) is used to evaluate anxiety and depression. Higher scores correspond to more anxiety and depression symptoms.
5 minutes
Physical Activity Assessment
Time Frame: 5 minutes
Physical activity levels is assessed using the International Physical Activity Questionnaire-Short Form (IPAQ-SF). The IPAQ requires respondents to estimate time spent in various levels of physical activity during the previous week. Scores for walking and moderate and vigorous activities are calculated as durations and frequencies multiplied by known metabolic equivalents per activity. The results for all activity-based items are summed for the total physical activity score. The participants were then categorized as inactive, minimally active and sufficiently active according to the IPAQ categorical classification.
5 minutes
Sleep Quality
Time Frame: 5 minutes
Sleep quality is evaluated using the Pittsburgh Sleep Quality Index (PSQI). The scale total score is between 0 and 21. A total score of 5 and above indicates poor sleep quality.
5 minutes
Disease Specific Quality of Life
Time Frame: 8 minutes
Disease-specific quality of life is evaluated using the Cystic Fibrosis Questionnaire-Revised (CFQ-R). The CFQ-R includes 50 items across 12 domains. Each domain is standardized on a 0-100 scale; higher scores indicate better quality of life.
8 minutes
General Health-Related Quality of Life
Time Frame: 5 minutes
Health-related quality of life is assessed using the Nottingham Health Profile (NHP). It is a general QOL questionnaire designed to measure perceived health problems and the extent to which these problems affect normal daily activities. It consists of 38 items in six dimensions (energy level, pain, physical mobility, emotional reactions, social isolation, and sleep). The total score for each section is 0-100. High scores indicate worse quality of life.
5 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Deniz Inal-Ince, PhD, HACETTEPE UNIVERSİTY

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 14, 2022

Primary Completion (Estimated)

December 1, 2023

Study Completion (Estimated)

December 1, 2023

Study Registration Dates

First Submitted

November 30, 2023

First Submitted That Met QC Criteria

December 8, 2023

First Posted (Estimated)

December 18, 2023

Study Record Updates

Last Update Posted (Estimated)

December 18, 2023

Last Update Submitted That Met QC Criteria

December 8, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cystic Fibrosis

3
Subscribe